PDS Biotechnology (PDSB) Liabilities and Shareholders Equity (2014 - 2026)

PDS Biotechnology (PDSB) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $30.5 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 32.77% year-over-year to $30.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $152.7 million (down 32.82% YoY) and the FY2025 annual result came in at $30.5 million, down 32.77% from the prior year.
• Liabilities and Shareholders Equity eased to $30.5 million in Q4 2025, from $34.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $77.4 million in Q2 2021 to a low of $27.8 million in Q1 2021.
• A 5-year average of $57.1 million and a median of $59.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 285.16% — and 2025, when it tumbled 33.83%.
• Tracing PDSB's Liabilities and Shareholders Equity over 5 years: stood at $67.2 million in 2021, then advanced by 14.6% to $77.0 million in 2022, then fell by 22.88% to $59.4 million in 2023, then slipped by 23.63% to $45.4 million in 2024, then plunged by 32.77% to $30.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $30.5 million (Q4 2025), $34.7 million (Q3 2025), and $40.5 million (Q2 2025), per Business Quant data.